POSTER SESSION V
Wednesday, March 2, 2011 — 9:30 AM - 12:00 Noon
Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
4
2007 ASCO/CAP Guidelines: Impact on HER 2 IHC Results.
(92)
G Acosta Haab, I Frahm, S Sarancone, V Caceres - Hospital Marie Curie, Buenos Aires, Argentina; Sanatorio Mater Dei, Buenos Aires, Argentina; Laboratorio Quantum, Rosario, Santa Fe, Argentina; Productos Roche, Tigre, Buenos Aires, Argentina
Cytogenetic Alterations in Her2/Neu Gene (HER2) and Chromosome 17 (chr17) by Fluorescent In-Situ Hybridization (FISH) in Immunohistochemically (IHC) Equivocal (2+) Breast Cancers.
(122)
DA Chitale, J Sanchez, A Adeyinka - Henry Ford Hospital, Detroit, MI; Henry Ford Hospital, Detroit
Progesterone Receptor (PR) Status and Tumor Grade . Key Factors in Predicting Oncotype DX Results.
(154)
S Frame, M Burge, P McGrath, H Wright, E Romond, M-L Fjallskog, L Samayoa - University of Kentucky, Lexington; VAMC, Lexington, KY; Uppsala University, Sweden; Instituto Internacional de Cancer, San Salvador, El Salvador
Effect of Ischemic Time, Fixation Time and Fixatives on Her-2/Neu IHC and FISH Results in Breast Cancer.
(206)
AC Lowe, G Nanjangud, IP Shintaku, S Shapourifar-Tehrani, N Rao, N Moatamed, D Lu, S Apple - UCLA, Los Angeles, CA
Correlation of Oncotype Dx Recurrence Score with Pathological Characteristics and Semiquantitative ER, PR and HER-2 Expression Score in Breast Cancer.
(274)
RK Virk, R Jaffar, D Kandil, RM Quinlan, A Khan - UMass Memorial Medical Center, Worcester, Ma; Children's Memorial Hospital, Northwestern University, Chicago, IL; UMass MemorialMedical Center, Worcester, Ma
Study of Concordance between RT-PCR and Immunohistochemical Testing of Hormone Receptor and HER2 Status in Breast Cancer Specimens.
(215)
R Mehta, RK Jain, PM Sojitra, Y Gokmen-Polar, S Badve - Indiana University School of Medicine, Indianapolis
FISH Testing for HER2 Expression May Yield Discordant Results Depending on Reporting Criteria Used.
(144)
SM Dintzis, KH Allison, RA Schmidt - University of Washington Medical Center, Seattle
Expression of Progesterone Receptor Is a Robust Marker for Long Term Survival in Breast Cancer.
(226)
S Nofech-Mozes, A Plotkin, SA Narod, P Sun, E Rawlinson, WM Hanna - University of Toronto, ON, Canada
Her2 Status Following Neoadjuvant Trastuzumab Therapy for Primary Breast Cancer.
(249)
MAG Sanders, AL Richardson, A Ly - Brigham and Women's Hospital, Boston, MA
Hormone Receptor and HER2 Profiles before and after Neoadjuvant Chemotherapy: Experience at Two Centers.
(135)
AD Corben, C D'Arcy, R Abi-Raad, A Bombonati, A Taghian, M Akram, FC Koerner, JH Eichhorn, EF Brachtel - Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital and Harvard Medical School, Boston
"High-ICR": A Unifying Data-Driven Reporting System for Her2 FISH Analysis Based on Intra-Tumor Heterogeneity.
(251)
RA Schmidt, SM Dintzis, KH Allison - University of Washington, Seattle
Histologic Image-Based Classifier for Predicting Outcome of ER+ Breast Cancers.
(103)
AN Basavanhally, S Ganesan, M Feldman, J Tomaszewski, A Madabhushi - Rutgers, The State University of New Jersey, Piscataway; The Cancer Institute of New Jersey, New Brunswick; Hospital of the University of Pennsylvania, Philadelphia
Discordance for Estrogen Receptor (ER) Status between Labs Is Still Very High, Despite ASCO/CAP Guidelines.
(284)
AW Welsh, M Harigopal, D Rimm - Yale University School of Medicine, New Haven, CT
button next to any title to add to Itinerary Planner...
Add
